tirzepatide cardiovascular outcomes for Heart Failure with Preserved Ejection Fraction and Obesity tirzepatide cardiovascular outcomes trial 2024

Contact your healthcare provider within 24 hours if you experience: Persistent vomiting (more than 24 hours) preventing adequate fluid intake Severe diarrhea (more than 6 episodes daily) lasting beyond 48 hours Inability to keep down fluids despite anti-nausea measures Weight loss exceeding 23 pounds in 24 hours (likely fluid loss) Markedly reduced urine output with dark, concentrated urine New or worsening dizziness affecting daily activities or causing falls Blood glucose readings consistently above target despite usual management Seek immediate medical attention (emergency department or call 911) for: Severe, persistent abdominal pain (may indicate pancreatitis or gallbladder disease, which are labeled risks of GLP-1 medications requiring immediate evaluation and drug discontinuation) [1] Severe dizziness or fainting episodes Rapid or irregular heartbeat with chest discomfort Confusion, disorientation, or altered mental status Inability to urinate for 12+ hours Signs of acute kidney injury (decreased urine output, swelling, severe fatigue) Symptoms of hyperglycemic emergencies in diabetes patients (excessive thirst, frequent urination, fatigue, fruity breath) Patients with pre-existing kidney disease, heart failure, or those taking multiple medications affecting fluid balance should maintain closer communication with their healthcare team

Let us know in the comments and follow for more

PRP Facial & Scalp Injections: The Natural Glow & Hair Regrowth Solution PRP injections undereyes before and after 2 treatments Wellness injections- Tirzepatide Tirzepatide is a novel medication similar to semaglutide and ozempic that has shown remarkable results in clinical trials for weight loss

Nations Ophthalmologists Respond to European Agencys New Recommendation

Efficacy and safety of modified fasting therapy for weight loss in 2054 hospitalized patients

Avoid using the medication if you have a history of medullary thyroid carcinoma, pancreatitis, severe gastrointestinal disorders, or multiple endocrine neoplasia type 2 (MEN2) syndrome